Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 142147. Отображено 100.
05-01-2012 дата публикации

Bone-like prosthetic implants

Номер: US20120003185A1
Автор: Shai Meretzki
Принадлежит: Individual

A prosthetic implant comprising a biocompatible three-dimensional scaffold and at least two cell types selected from the group consisting of osteoblasts, osteoclasts, and endothelial cells or progenitors thereof.

Подробнее
05-01-2012 дата публикации

Methods and compositions for modulating proline levels

Номер: US20120003207A1
Автор: Mike A. Clark
Принадлежит: ONCOPHARMACOLOGICS Inc

Methods and compositions for modulating amino acid levels in a subject are provided herein.

Подробнее
05-01-2012 дата публикации

Biomarkers for inhibitors with anti-angiogenic activity

Номер: US20120004129A1
Автор: Joyce Behrens
Принадлежит: Merck Patent GmBH

The invention relates to a method for assessing the effect of integrin inhibitors and small molecule ATP site directed multi kinase inhibitors on angiogenesis by the use of certain identified biomarkers. This method is notably beneficial for the determination of the efficacy of integrin inhibitors and small molecule ATP site directed multi-kinase inhibitors mainly used for the treatment of angiogenesis associated diseases such as cancer. Especially, the invention relates to biomarkers linked to angiogenesis that are preferably accessible in body fluids and therefore allow analysis of target modulation in a non-invasive way. The use of said biomarkers for the screening of compounds with integrin-inhibitory activity is also disclosed.

Подробнее
12-01-2012 дата публикации

Renal cell carcinoma biomarkers

Номер: US20120009201A1

Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker.

Подробнее
12-01-2012 дата публикации

Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound

Номер: US20120010405A1
Принадлежит: Individual

The present invention provides a compound of the formula (III): wherein R is a C 1-6 alkyl group, as a novel optically active intermediate for preparing tetrahydropyrrolo[1,2-a]pyrazin-4-spiro-3′-pyrrolidine derivatives such as Ranirestat being a promising therapeutic agent for diabetic complications in a short process, in an economically advantageous manner and in high yields, and the process for preparing the same.

Подробнее
19-01-2012 дата публикации

Tablet formulation

Номер: US20120012499A1
Принадлежит: Novo Nordisk AS

The present invention relates to a pharmaceutical fixed dose combination tablet comprising repaglinide and metformin. The present invention also provides a method of producing said tablet.

Подробнее
19-01-2012 дата публикации

Pharmaceutical composition for treating or preventing cancer

Номер: US20120016019A1
Автор: Gee-Hwoon LEE
Принадлежит: Individual

The present invention relates to a compound of the formula I: wherein R is C 2 H 5 or C 2 H 3 , or a pharmaceutically acceptable salt or hydrate thereof, and a process for preparing said compound of the formula I. The invention also relates to the use of a composition comprising said compound of the formula I or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, for treating or preventing cancers.

Подробнее
19-01-2012 дата публикации

Diastereoisomers of hypophosphorous acid derivatives

Номер: US20120016155A1

The invention relates to the diastereoisomers of hypophosphorous acid derivatives, having formula (I), wherein the phenyl group is substituted by one or several atoms or groups, occupying one or several positions on the phenyl ring, and a method for the separation thereof.

Подробнее
26-01-2012 дата публикации

Leukemia inhibitory factor (lif) for use in repressing human papillomavirus (hpv) transcription

Номер: US20120020914A1
Принадлежит: Leland Stanford Junior University

Embodiments of the invention are related to leukemia inhibitory factor (LIF) for use in repressing human papillomavirus (HPV) transcription. Processes and related kits are described for treating a HPV-associated papillomatous proliferation, for treating a HPV-associated genital, anal, vulvar, penile, oral, or laryngeal wart, for treating HPV-associated cervical dysplasia or cervical cancer, and for repressing HPV transcription, by administering LIF to a patient in need thereof. A related embodiment is treatment of HPV-16 by use of LIF.

Подробнее
26-01-2012 дата публикации

Thermosensitive hydrogel composition and method

Номер: US20120020932A1
Принадлежит: Zimmer Orthobiologics Inc

A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment.

Подробнее
26-01-2012 дата публикации

Combination of an insulin and a glp-1-agonist

Номер: US20120021978A1
Принадлежит: Sanofi Aventis Deutschland GmbH

The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.

Подробнее
02-02-2012 дата публикации

Methods for treating diabetes

Номер: US20120027729A1
Принадлежит: Tulane University

Transplantation of multipotent stromal cells (MSCs) into diabetic mice lowers blood sugar, increases blood insulin levels, increases the number and size of islets, and improves renal pathology. Accordingly, the invention provides methods for treating or preventing diabetes by administering isolated MSCs. The invention also provides methods for treating or preventing complications which arise from diabetes, including diabetic nephropathy, by transplanting isolated MSCs.

Подробнее
02-02-2012 дата публикации

Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers

Номер: US20120027779A1

The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumour cell apoptosis in the context of an anticancer treatment.

Подробнее
02-02-2012 дата публикации

Method of preparing lipid nanoparticles

Номер: US20120027825A1

The present invention relates to a useful method for preparing nanocapsules having a liquid lipid core and a solid shell and charged with at least one active agent having a hydrophilic character, said method comprising at least the steps consisting in: i) providing at least a first microemulsion having a water-in-oil character, stabilized by at least one lipophilic surfactant and containing in its hydrophilic phase at least one active agent having a hydrophilic character, providing at least a second microemulsion, separate from the first microemulsion, formulated by phase inversion of an emulsion and stabilized by at least one heat-sensitive, nonionic hydrophilic surfactant; iii) adding said first microemulsion to said second microemulsion under conditions propitious for the formation of a novel microemulsion architecture in which said hydrophilic active agent remains present in the hydrophilic phase of the first microemulsion; and iv) chill-hardening the mixture formed in the previous step, so as to obtain nanocapsules comprising said hydrophilic active agent and being formed from a lipid core, which is liquid at room temperature, and encapsulated in a film which is solid at room temperature. Further, the invention relates to nanocapsules which are able to be obtained by said method.

Подробнее
02-02-2012 дата публикации

Whitefly Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof

Номер: US20120028300A1
Принадлежит: Intrexon Corp

The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.

Подробнее
02-02-2012 дата публикации

Nitroxide Free Radical Synergized Antineoplastic Agents

Номер: US20120029021A1
Автор: Errol V. Mathias, Yong Ba
Принадлежит: California State University

Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the products formed from the adducts after administration.

Подробнее
02-02-2012 дата публикации

Crystalline form of sunitinib and processes for its preparation

Номер: US20120029046A1
Принадлежит: Generics UK Ltd

The present invention relates to a novel crystalline form of sunitinib free base designated form I and to processes for its preparation. The invention also relates to its use as an API and in the preparation of various forms of sunitinib. Further, the invention relates to pharmaceutical compositions comprising the novel crystalline form and salts, solvates and hydrates prepared according to the invention, and to the uses of said pharmaceutical compositions in the treatment and/or prevention of cancer.

Подробнее
02-02-2012 дата публикации

Compositions for treating or preventing obesity and insulin resistance disorders

Номер: US20120029065A1
Принадлежит: General Hospital Corp, Harvard College

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.

Подробнее
09-02-2012 дата публикации

Ophthalmic preparation containing menthyl ester of indomethacin

Номер: US20120034278A1
Принадлежит: Alpharx Inc

There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation.

Подробнее
09-02-2012 дата публикации

Process for preparation of high-purity meloxicam and meloxicam potassium salt

Номер: US20120035162A1
Принадлежит: Individual

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Подробнее
16-02-2012 дата публикации

Compositions and methods for diagnosing prostate cancer based on detection of slc45a3-elk4 fusion transcript

Номер: US20120039887A1
Принадлежит: CORNELL UNIVERSITY

RNA transcripts representing a fusion of a human SLC45A3 nucleic acid and a human ELK4 nucleic acid that are associated with prostate cancer are described. Compositions and methods useful for detection of fusion transcripts of human SLC45A3 and ELK4 genetic sequences associated with cancer and useful for cancer therapy are provided.

Подробнее
16-02-2012 дата публикации

Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders

Номер: US20120040940A1
Принадлежит: Pharnext SA

The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signaling and thyroid hormone pathway in a subject.

Подробнее
16-02-2012 дата публикации

Method for the manufacture of degarelix

Номер: US20120041172A1
Принадлежит: PolyPeptide Laboratories AS

In a step-wise synthesis of degarelix comprising 0.3% by weight or less of 4-([2(5-hydantoyl)]acetylamino)-phenylalanine analog on (solid support)-NH 2 a step comprises providing a solution of an amino acid or peptide of which the α-amino group is protected by Fmoc; contacting the support with the solution in the presence of reagent for forming a peptide bond between a carboxyl group of the amino acid or peptide and (solid support)-NH 2 ; removing Fmoc by contacting the support with an organic base, in particular piperidine, in an organic solvent. Also disclosed is degarelix of high purity prepared by the method of the invention and the use of Fmoc in the synthesis of degarelix.

Подробнее
16-02-2012 дата публикации

Method of controlled drug release from a liposome carrier

Номер: US20120041357A1
Принадлежит: University of Arkansas

Disclosed are methods and compositions for the controlled release of a drug or agent from a liposome using light or radiation. Also disclosed are compositions comprising liposomes having a lipid layer, wherein the liposomes contain an agent, an enzyme capable of releasing the agent from the liposome, and an enzyme activator sequestered by a molecular cage. In another aspect, methods of delivering an agent to a target in a subject are disclosed.

Подробнее
23-02-2012 дата публикации

Policosanol nanoparticles

Номер: US20120045482A1
Принадлежит: NanoRx Inc

The present invention provides nanoparticulate policosanol, and octacosanol formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions.

Подробнее
01-03-2012 дата публикации

Composition and a method for producing contrast agent using the composition

Номер: US20120052011A1
Принадлежит: Canon Inc

A composition including a hydrophilic dye having a sulfonate group and a hydrophobic solvent, wherein the composition includes at least one of a nicotinic acid derivative and a tiamine derivative, can form densely accumulated particles and the like since the composition includes a hydrophilic dye that is likely to dissolve in a hydrophobic solvent.

Подробнее
01-03-2012 дата публикации

ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN TUMOR SUPPRESSING SUBTRANSFERABLE CANDIDATE 4 (TSSC4)

Номер: US20120053232A1
Автор: James W. Ryan
Принадлежит: RYOGEN LLC

Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.

Подробнее
15-03-2012 дата публикации

Novel Target for Regulating Multiple Sclerosis

Номер: US20120064092A1

Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.

Подробнее
15-03-2012 дата публикации

Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates

Номер: US20120064097A1
Принадлежит: WASHBURN THERAPEUTICS Inc

We provide monoclonal antibodies against interleukin-1β and tumor necrosis factor-α that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the invention inhibited cytokine signaling to comparable levels as that of unmodified antibodies. Conjugation of cytokine-neutralizing antibodies to high molecular weight polymers enhances the affinities cytokine-binding moieties used as anti-inflammatory therapeutics.

Подробнее
15-03-2012 дата публикации

Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same

Номер: US20120064150A1
Принадлежит: Polytechnic Institute of NYU

The present invention provides a biocompatible material in the form of a solid, a water insoluble cross-linked gel or a liposome, which contains a stable comples of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan.

Подробнее
15-03-2012 дата публикации

Rna molecules and therapeutic uses thereof

Номер: US20120065246A1
Автор: Pal Saetrom
Принадлежит: Mina Therapeutics Ltd

The invention relates to double-stranded RNA molecules in which each strand of said molecule possesses: (a) sufficient complementarity to a target mRNA molecule to facilitate cleavage thereof; and (b) sufficient complementarity to the other strand of the double-stranded RNA molecule so as to form a stable duplex; and in which at least one strand of said molecule possesses: (c) a seed region of complementarity to at least one seed site present in a 3′ untranslated region of at least one target mRNA molecule. The invention also relates to an algorithm for the design of a double-stranded RNA molecule in which each strand of said molecule possesses: (a) sufficient complementarity to a target mRNA molecule to facilitate cleavage thereof; and (b) sufficient complementarity to the other strand of the double-stranded RNA molecule so as to form a stable duplex; and in which at least one strand of said molecule possesses: (c) a seed region of complementarity to at least one seed site present in a 3′ untranslated region of at least one target mRNA molecule; wherein said algorithm comprises the steps: (i) input a population of mRNA sequences transcribed from one or more genes of interest; (ii) identify all subsequences of at least 12 nucleotides in length within the population of step (i) which are complementary to another subsequence of at least 12 nucleotides in length in the population; (iii) determine a list of candidate bi-functional double-stranded RNA molecules, said list comprising the double-strand RNA duplexes comprising the two complementary subsequences of step (ii); and (iv) sort the list of candidate double-stranded RNA molecules of step (iii) based on their potential to cause translational suppression.

Подробнее
15-03-2012 дата публикации

siRNA Targeting Apolipoprotein B (APOB)

Номер: US20120065250A1
Принадлежит: Dharmacon Inc

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.

Подробнее
22-03-2012 дата публикации

Low-Density Magnesium-Aluminum-Silicate (MAS) Microparticles for Radiotherapy and/or Radioimaging

Номер: US20120070371A1
Автор: Delbert E. Day, Yiyong He
Принадлежит: Individual

This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles that contain either samarium-yttrium, samarium, or lutetium as medical isotopes for radiotherapy and/or radioimaging.

Подробнее
22-03-2012 дата публикации

Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates

Номер: US20120071491A1
Принадлежит: Nektar Therapeutics

The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water-soluble, non-peptidic oligomer.

Подробнее
22-03-2012 дата публикации

Method for producing olmesartan medoxomil

Номер: US20120071665A1
Автор: Shigeo Yanagihara
Принадлежит: Daiichi Sankyo Co Ltd

A method for producing high-purity olmesartan medoxomil is provided in which a solvent containing water is used in steps of tritylation and DMDO esterification of olmesartan.

Подробнее
29-03-2012 дата публикации

Novel salts of sitagliptin

Номер: US20120077760A1
Автор: Ivan Plantan, Lovro Selic
Принадлежит: Lek Pharmaceuticals dd

The present invention relates to novel pharmaceutically acceptable salts of sitagliptin, to processes for their preparation and to pharmaceutical compositions containing them.

Подробнее
05-04-2012 дата публикации

Cell proliferation inhibitor

Номер: US20120082986A1
Принадлежит: Nagoya University NUC

The present inventors revealed a TTF-1-specific oncogenic process by elucidating the molecular mechanism regulated by the master regulatory factor TTF-1. The present inventors focused on the elucidation of the essence of the lineage-specific survival signal which is a novel canceration signal. Thus, the present inventors found that the expression of ROR1, which is a receptor tyrosine kinase, is induced by the master regulatory factor TTF-1, and demonstrated the presence of a characteristic canceration signal transduction system.

Подробнее
12-04-2012 дата публикации

Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations

Номер: US20120088726A1
Принадлежит: Alfa Wasserman SpA

Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Подробнее
19-04-2012 дата публикации

Ipp complex as marker for erlotinib treatment

Номер: US20120095029A1
Принадлежит: Hoffmann La Roche Inc

The present invention provides biomarkers which are predictive for the clinical benefit of erlotinib hydrochloride treatment in cancer patients.

Подробнее
19-04-2012 дата публикации

Triglyceride-lowering agent and hyperinsulinism-ameliorating agent

Номер: US20120095043A1
Автор: Taro Aoki, Toru Yokoyama
Принадлежит: Kowa Co Ltd, Nissan Chemical Corp

The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.

Подробнее
26-04-2012 дата публикации

Regionalised endoderm cells and uses thereof

Номер: US20120100115A1
Принадлежит: University of Edinburgh

The present invention relates to the generation of anterior definitive endoderm (ADE) cells from embryonic stem cells and the differentiation of such cells to, for example, pancreatic or liver cells. The invention also relates to cell lines, cell culture methods, cells markers and the like and their potential uses in a variety of applications.

Подробнее
26-04-2012 дата публикации

Inhibition of secretion from non-neuronal cells

Номер: US20120101027A1
Принадлежит: Syntaxin Ltd

The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.

Подробнее
03-05-2012 дата публикации

Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference

Номер: US20120107389A1
Принадлежит: Individual

The present invention provides method and pharmaceutical composition for efficient delivery of siRNA (small interfering ribonucleic acids) into cultured mammalian cells. In addition, the present invention provides methods and compositions for knocking down the expression of a specific target gene by treating cells with the formulations comprising cationic amphiphile, a neutral colipid and a small RNA molecule. We demonstrate that our method delivers siRNA efficaciously into animal cells for the purpose of RNA interference. The area of medical science that is likely to benefit most from the present invention is RNAi therapeutics.

Подробнее
03-05-2012 дата публикации

N1/n2-lactam acetyl-coa carboxylase inhibitors

Номер: US20120108619A1
Принадлежит: PFIZER INC

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Подробнее
10-05-2012 дата публикации

Collagen extraction from aquatic animals

Номер: US20120114570A1
Принадлежит: UNIVERSITI PUTRA MALAYSIA (UPM)

The present invention relates to the use of fish skin as novel industrial source of collagen. Advantageously, said skin is obtained after the filleting or cutting of the fresh fish and frozen immediately after filleting/cutting, thus guaranteeing a very good quality of the base material, both from the bacteriological standpoint and from the standpoint of the native property of the protein.

Подробнее
10-05-2012 дата публикации

Methods for inhibiting cutaneous inflammation and hyperpigmentation

Номер: US20120114575A1
Автор: B. Jack Longley
Принадлежит: Columbia University of New York

This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treating contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.

Подробнее
10-05-2012 дата публикации

High efficiency encapsulation of charged therapeutic agents in lipid vesicles

Номер: US20120114831A1
Принадлежит: University of British Columbia

Methods for the preparation of a lipid-nucleic acid composition are provided. According to the methods, a mixture of lipids containing a protonatable or deprotonatable lipid, for example an amino lipid and a lipid such as a PEG- or Polyamide oligomer-modified lipid is combined with a buffered aqueous solution of a charged therapeutic agent, for example polyanionic nucleic acids, to produce particles in which the therapeutic agent is encapsulated in a lipid vesicle. Surface charges on the lipid particles are at least partially neutralized to provide surface-neutralized lipid-encapsulated compositions of the therapeutic agents. The method permits the preparation of compositions with high ratios of therapeutic agent to lipid and with encapsulation efficiencies in excess of 50%.

Подробнее
10-05-2012 дата публикации

Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders

Номер: US20120115831A1
Автор: Richard Hausknecht
Принадлежит: Individual

The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible.

Подробнее
10-05-2012 дата публикации

Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Номер: US20120115920A1
Принадлежит: Theravance Inc

The invention provides crystalline salt forms of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]-imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compounds, processes and intermediates for preparing the crystalline compounds, and methods of using the crystalline compounds to treat diseases such as hypertension.

Подробнее
10-05-2012 дата публикации

Selective inhibitors of cb2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders

Номер: US20120115931A1
Принадлежит: Individual

The invention relates to a method for treating and/or preventing obesity and/or obesity-related disorders by administering to a subject in need thereof a selective inhibitor of cannabinoid type 2 (CB2) receptor expression.

Подробнее
10-05-2012 дата публикации

Inhibitors of anaphase promoting complex activity

Номер: US20120115948A1
Принадлежит: Harvard College

The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibing the ubiquitination activity of the APC by administering compositions of the invention.

Подробнее
17-05-2012 дата публикации

cRGD PEPTIDE DERIVATIVE AND ITS MANUFACTURE, AND IMPLANT HAVING A COATING CONTAINING A cRGD PEPTIDE DERIVATIVE

Номер: US20120121682A1
Автор: Alexander Borck
Принадлежит: BIOTRONIK AG

Various embodiments of the invention relate to a cRGD peptide derivative and an associated manufacturing method, and to an implant having a coating containing a cRGD peptide derivative. One aspect of the invention is the provision of a cRGD peptide derivative having the formula (1): wherein x=0-8, in particular 4-8, and R is a hydrophobic group.

Подробнее
17-05-2012 дата публикации

Pharmaceutical composition for transdermal or transmucous administration

Номер: US20120122829A1
Принадлежит: BESINS Healthcare Luxembourg SARL

The present invention relates to a novel pharmaceutical composition for transdermal or transmucous administration of at least one active substance, and comprising especially a fatty acid as a percutaneous absorption promoter, at least one alcoholic vehicle and also a stabilizer capable of stabilizing the fatty acid in the said pharmaceutical composition.

Подробнее
17-05-2012 дата публикации

Autoantibody production inhibitor

Номер: US20120123099A1
Автор: Masayuki Homma
Принадлежит: Nihon Pharmaceutical Co Ltd

The present invention provides an autoantibody production inhibitor which can specifically suppress the autoantibodies and which can effectively prevent or treat the autoimmune disease of autoantibody type. According to the present invention, there is provided an autoantibody production inhibitor comprising, as an effective ingredient, a fusion protein which consists of a protein (X) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type and a protein (A) containing a fragment which exhibits the antibody-dependent cellular cytotoxicity of the antibody heavy chain constant region.

Подробнее
17-05-2012 дата публикации

Therapeutic regimen for treating cancer

Номер: US20120123186A1
Принадлежит: Genvec Inc

The invention provides a method for treating locally advanced resectable esophageal cancer in a human comprising (a) administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding a human TNF-α and operably linked to a promoter, wherein the dose comprises about 4×10 7 to about 4×10 12 particle units (pu) of adenoviral vector, at least once in a therapeutic period comprising up to about 10 weeks, (b) administering a dose of ionizing radiation to the human over the duration of the therapeutic period, and (c) administering a dose of one or more chemotherapeutics to the human over the duration of the therapeutic period, whereby the locally advanced resectable esophageal cancer in the human is treated.

Подробнее
24-05-2012 дата публикации

Compositions and methods for kinase-mediated cytoprotection and enhanced cellular engraftment and persistence

Номер: US20120128631A1
Автор: Mark A. Sussman

Disclosed are methods of protecting cells, especially non-vascular system, non-hematopoietic cells and tissues, from apoptosis and enhancing their engraftment, survival, and/or persistence by providing enhanced levels of PIM activity for the cell, including PIM-1 activity. Also disclosed are cells that have been engineered to express enhanced levels of PIM kinase, and methods of administering those cells to vertebrates.

Подробнее
24-05-2012 дата публикации

Method of preparing pluripotent stem cells

Номер: US20120129256A1

The invention relates to biotechnology, and particularly to the preparation of pluripotent stem cells. The method involves introduction into umbilical cord and placental stem cells of RNA with at least one sequence which ensures the transition of cells to the pluripotent state. The method enables to effectively prepare pluripotent stem cells from the cells of mammalian placenta and umbilical cord which have not yet acquired somatic mutations, which reduces the risk of oncogenesis and other adverse effects of reprogramming.

Подробнее
24-05-2012 дата публикации

Photochemotherapeutic heterocyclic agents having antiproliferative and antineoplastic activity

Номер: US20120129884A1
Принадлежит: UNIVERSITA DEGLI STUDI DI PADOVA

The present invention concerns the synthesis of new analogs of angelicins, pyrrolo [3,2-h]quinoline, for the treatment of pathologies having hyperproliferative character included those having neoplastic nature. The treatment is based on the combined action of pyrrolo [3,2-h]quinolines and UV-A light, through a clinical approach defined as PUVA (psoralen-UVA light). The most important feature of these compounds is that they exert their remarkable photoxicity without any DNA damage, which is the main origin of the side effects of the PUVA therapy.

Подробнее
24-05-2012 дата публикации

Dual-acting antihypertensive agents

Номер: US20120129900A1
Принадлежит: Theravance Inc

The invention is directed to compounds of formula I: wherein Ar, r, R 3 , X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.

Подробнее
31-05-2012 дата публикации

Gum arabic coated 198gold radioactive nanoparticles for cancer therapy

Номер: US20120134918A1
Принадлежит: University of Missouri System

The invention provides a cancer therapeutic and imaging agent comprising a solution containing Gum Arabic coated 198 Au nanoparticles. The Gum Arabic coated 198 Au nanoparticles have been demonstrated experimentally shown to have a surprising efficacy for a single dose direct injection, reducing tumors in analog mice by 82% over a short period of time. The particles of the invention have a believed optimal size for therapy and imaging applications, and can be used as a theranostic agent in the treatment of needle accessible cancers. The invention also provides a method for forming Gum Arabic coated 198 Au nanoparticles. A gold foil is irradiated to produce 198 Au foil. The foil is dissolved to form radioactive gold salt. The salt is dried, and then reconstituted to form a 198 Au nanoparticle precursor. The precursor is reduced with a reducing agent in an aqueous solution including Gum Arabic to form Gum Arabic coated 198 Au nanoparticles.

Подробнее
31-05-2012 дата публикации

Nanoparticulate telmisartan compositions and process for the preparation thereof

Номер: US20120135053A1
Принадлежит: NANOFORM HUNGARY Ltd

The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.

Подробнее
31-05-2012 дата публикации

Compositions containing mixtures of fermentable fibers

Номер: US20120135957A1
Принадлежит: COSUCRA GROUPE WARCOING SA, DF3 SAS

The present invention relates to synergistic compositions comprising mixtures of fermentable fibers. The present invention specifically relates to composition comprising inulin and arabinoxylan for use in reducing, preventing and/or treating inflammation, wherein said arabinoxylan is partially hydrolyzed arabinoxylan and wherein the ratio of said inulin to said arabinoxylan and/or partially hydrolyzed arabinoxylan is between 65%/35% by weight and 90%/10% by weight.

Подробнее
31-05-2012 дата публикации

Substituted acylanilides and methods of use thereof

Номер: US20120136052A1

This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

Подробнее
07-06-2012 дата публикации

Materials and Methods for the Treatment of Hypertension

Номер: US20120141424A1
Принадлежит: Vegenics Pty Ltd

The present invention is directed to materials and methods for the treatment of hypertension and ischemia comprising administering at least one therapeutic agent selected from the group consisting of vascular endothelial growth factor-C product and vascular endothelial growth factor-D product, and optionally, when treating hypertension, a standard of care anti-hypertensive agent.

Подробнее
07-06-2012 дата публикации

Compositions and methods for promoting beta cell maturity

Номер: US20120141436A1
Принадлежит: Joslin Diabetes Center Inc

Compositions and methods for providing an enriched population of mature, glucose-responsive insulin secreting cells, and for modulating insulin expression, activity and secretion in a subject.

Подробнее
07-06-2012 дата публикации

Treatment of non-proliferative cystic disease

Номер: US20120141506A1
Автор: David L. KLEINBERG
Принадлежит: New York University NYU

The present invention relates generally to the treatment of non-proliferative cystic disease of the breast. More particularly, the present invention relates generally to the treatment of non-proliferative cystic disease of the breast in BRCA1 mutant carriers. Accordingly, the invention relates to the use and application of compounds or agents, including somatostatin analogs, that inhibit insulin-like growth factor I (IGF-I) or insulin-like growth factor I receptor signaling for the treatment of non-proliferative cystic disease of the breast. The invention further relates to the use and application of these compounds or agents for the treatment of non-proliferative cystic disease of the breast in BRCA1 patients. The invention also relates to use of somatostatin analog SOM230 in treatment of non-proliferative cystic disease of the breast and more particularly, to use of somatostatin analog SOM230 in treatment of BRCA1 associated non-proliferative cystic disease.

Подробнее
07-06-2012 дата публикации

Combination of organic compounds

Номер: US20120142638A1
Автор: Randy Lee Webb
Принадлежит: Individual

The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising a therapeutic agent acting on the renin-angiotensin system (RAS) or a pharmaceutically acceptable salt thereof and comprising at least one CB1 antagonist, or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use of such a combination for the prevention of, delay of progression of, treatment of diseases and disorders that may be modulated by action on the renin-angiotensin system (RAS), appetency disorders or substance abuse disorders.

Подробнее
07-06-2012 дата публикации

Targetted drug delivery to the bone

Номер: US20120142641A1
Принадлежит: NANYANG TECHNOLOGICAL UNIVERSITY

The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.

Подробнее
07-06-2012 дата публикации

Crystalline compound of 7-[(3r)-3-amino-1-oxo-4-(2, 4, 5-trifluorphenyl)butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluormethyl)-1, 2, 4 -triazolo[4,3-a]pyrazin

Номер: US20120142693A1
Принадлежит: SANDOZ AG

A crystalline compound of 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (INN: Sitagliptin) of formula 1 with fumaric acid or a hydrate thereof, where the molar ratio of the compound of formula 1 to fumaric acid is 1:0.6 to 1:1.3 is described.

Подробнее
07-06-2012 дата публикации

Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States

Номер: US20120142781A1
Автор: Ibert Clifton Wells
Принадлежит: Magnesium Diagnostics Inc

This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds.

Подробнее
07-06-2012 дата публикации

Proteasome inhibitors having chymotrypsin-like activity

Номер: US20120142917A1

Disclosed herein is the use of HLM-008182, as well as its analogues formed via in-house synthesis, as a potent proteasome inhibitors. A new method was developed for HLM-008182 through a four-step protocol and the method was further optimized to a two step protocol. The synthesis in both protocols was regioselective with TiCl 4 . The reaction was highly efficient with microwave assisted heating and THF as solvent. The modification around the molecule HLM-008182 established primary SAR, indicating that the proteasome inhibition activity was a function of the 2-side chain.

Подробнее
14-06-2012 дата публикации

Genetic Variants in the TCF7L2 Gene as Diagnostic Markers for Risk of Type 2 Diabetes Mellitus

Номер: US20120149016A1
Автор: Struan F.A. Grant
Принадлежит: DECODE GENETICS EHF

Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes.

Подробнее
14-06-2012 дата публикации

Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom

Номер: US20120149633A1
Автор: Juan Anguita

Salp15, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed. Salp15 gene products and Salp15 polypeptide fragments have biological activity in modulating CD4+ T cell activation through specific binding to CD4. Thus, therapeutic methods involving modulating T cell activation using Salp15 and biologically active polypeptide fragments thereof are also disclosed. The specific binding of Salp15 and fragment peptides thereof to CD4 can inhibit HIV infection of T cells, and thus methods of using Salp15 for inhibiting HIV infection are also disclosed. Screening methods for selecting substances having an ability to modulate activation of T cells are also disclosed.

Подробнее
21-06-2012 дата публикации

Treatment of menopause-associated symptoms

Номер: US20120157424A1
Принадлежит: Besins Healthcare SA

Described are estradiol-containing pharmaceutical compositions and, and methods using the same to alleviate menopause-related symptoms, such as hot flushes, by topically administering estradiol at low effective doses.

Подробнее
21-06-2012 дата публикации

Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase

Номер: US20120157456A1
Принадлежит: Janssen Pharmaceutica NV

This invention comprises the novel compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X and Y have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

Подробнее
28-06-2012 дата публикации

Zona pellucida binding peptides, expression vectors, compositions, and methods for species-specific immunocontraception of animals

Номер: US20120164165A1
Принадлежит: AUBURN UNIVERSITY

Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines.

Подробнее
28-06-2012 дата публикации

P53 fusion proteins and methods of making and using thereof

Номер: US20120165268A1
Принадлежит: Proteom Tech Inc

Biologically active tetrameric p53 proteins and p53 fusion proteins are provided. These proteins may be generated and refolded into tetrameric form using denatured proteins produced from E. coli . Therapeutic uses of p53 proteins and p53 fusion proteins are also provided.

Подробнее
05-07-2012 дата публикации

Mass spectrometric quantitation assay for metabolites of leflunomide

Номер: US20120171151A1
Автор: Karin O. Thomassian
Принадлежит: Individual

Methods are described for determining the amount of metabolites of leflunomide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying teriflunomide in a sample.

Подробнее
05-07-2012 дата публикации

Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides

Номер: US20120171192A1
Автор: Jian Yuan, Zhenkun Lou

This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided. This document also provides methods and materials for identifying agonists or antagonists of USP10 polypeptide mediated stabilization of p53 polypeptides.

Подробнее
05-07-2012 дата публикации

Use of pkc-zeta as a breast cancer tumorigenic biomarker as well as a target for treatment of breast cancer

Номер: US20120171219A1

The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.

Подробнее
05-07-2012 дата публикации

SOGA Polynucleotides and Polypeptides and Uses Thereof

Номер: US20120174243A1

The present invention relates to the identification of polynucleotides and polypeptides involved in insulin and adiponectin signaling and regulation of glucose production. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of glucose production and the monitoring and treatment of metabolic disorders such as diabetes.

Подробнее
12-07-2012 дата публикации

Compositions, methods, and systems comprising fluorous-soluble polymers

Номер: US20120177578A1
Принадлежит: Massachusetts Institute of Technology

The present invention generally relates to compositions, methods, and systems comprising polymers that are fluorous-soluble and/or organize at interfaces between a fluorous phase and a non-fluorous phase. In some embodiments, emulsions or films are provided comprising a polymer. The polymers, emulsions, and films can be used in many applications, including for determining, treating, and/or imaging a condition and/or disease in a subject. The polymer may also be incorporated into various optoelectronic device such as photovoltaic cells, organic light-emitting diodes, organic field effect transistors, or the like. In some embodiments, the polymers comprise pi-conjugated backbones, and in some cases, are highly emissive.

Подробнее
12-07-2012 дата публикации

Klotho protein and related compounds for the treatment and diagnosis of cancer

Номер: US20120178699A1

Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents.

Подробнее
12-07-2012 дата публикации

DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES

Номер: US20120178734A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Подробнее
12-07-2012 дата публикации

Lactam compounds useful as protein kinase inhibitors

Номер: US20120178739A1
Принадлежит: Millennium Pharmaceuticals Inc

The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Подробнее
12-07-2012 дата публикации

Treatment of liver disorders with p13k inhibitors

Номер: US20120178767A1
Автор: Roger G. Ulrich
Принадлежит: Gilead Calistoga LLC

The invention provides methods to treat certain liver disorders by administering a compound that inhibits PD K isoforms, particularly the delta isoform. It further provides specific compounds useful for these methods and ways to identify subjects who are particularly suitable for receiving these treatments.

Подробнее
19-07-2012 дата публикации

Methods of promoting fat loss comprising administering an alk7 inhibitor

Номер: US20120183540A1
Автор: Jasbir Seehra, John Knopf
Принадлежит: Acceleron Pharma Inc

The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.

Подробнее
19-07-2012 дата публикации

Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone

Номер: US20120183615A1
Принадлежит: Shionogi and Co Ltd

A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.

Подробнее
19-07-2012 дата публикации

Methods for treating inflammation

Номер: US20120184616A9
Принадлежит: Individual

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

Подробнее
26-07-2012 дата публикации

Orally administered bacteria as vehicles for systematic delivery of agents

Номер: US20120189550A1
Принадлежит: University College Cork

The current invention relates to the use of a bacterial species in the preparation of a composition adapted for oral administration for the delivery of an agent to a site in the body. The site in the body may be an organ or a tumour site. The bacterial species is a food grade, non-pathogenic, gram-positive bacteria capable of anaerobic growth.

Подробнее
26-07-2012 дата публикации

Oral dosage forms

Номер: US20120189693A1
Принадлежит: Elite Laboratories Inc

Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm and comprises at least about 0.01 weight percent of at least one pharmaceutically active agent that is distributed substantially throughout said microtablet. Additional aspects of the present invention are directed to methods for producing compressed microtablets having a major dimension that is between about 0.25 mm and about 1.0 mm.

Подробнее
02-08-2012 дата публикации

Tumor tissue-selective bio-imaging nanoparticles

Номер: US20120195835A1
Автор: Kyoungja Woo, Myung-Ik YOO

A bio-imaging nanoparticle is composed of a core nanoparticle, a bonding layer having organic ligands, surfactants and polyoxyalkylene derivatives of fatty acid ester, and veiling the core nanoparticle, and functional molecules, wherein the organic ligands are bound to a surface of the core nanoparticle, the surfactants are bound to a portion of the surface of the core nanoparticle to which the organic ligands are not bound, the polyoxyalkylene derivatives of the fatty acid ester are introduced in an empty space between the organic ligands and the surfactants of the bonding layer, and the functional molecule is bound to a second terminal end opposite to a first terminal end of both terminal ends of the organic ligand, the first terminal end of the organic ligand being bound to a shell of the core nanoparticle.

Подробнее
02-08-2012 дата публикации

Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Номер: US20120195889A1
Принадлежит: Bristol Myers Squibb Co

EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.

Подробнее
02-08-2012 дата публикации

Methods for transdifferentiation of body tissues

Номер: US20120196826A1
Автор: Steven Baranowitz
Принадлежит: Individual

The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune disease.

Подробнее
02-08-2012 дата публикации

Antidepressant Oral Liquid Compositions

Номер: US20120196917A1
Автор: Ramesh Sesha
Принадлежит: Wockhardt Ltd

The invention provides for the first time an oral liquid composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and a buffering agent was used to stabilize the acid sensitive duloxetine. The composition has duloxetine from about 0.1 mEq to about 2.5 mEq per mg of duloxetine. The invention further discloses an oral liquid composition of duloxetine or its pharmaceutically equivalent derivative wherein the degradation product 1-Naphthol is less than 0.01%. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.

Подробнее
02-08-2012 дата публикации

PREVENTING ISLET INFLAMMATION AND DYSFUNCTION AND MAINTAINING PROPER GLUCOSE LEVELS BY CONTROLLING eIF5A AND ITS HYPUSINATION

Номер: US20120196918A1

Pancreatic islet dysfunction, in both type 1 and type 2 diabetes results, in part, from cytokine-mediated inflammation leading to iNOS generation and the death of pancreatic islets. The production of pro-inflammatory cytokines involved in the generation of iNOS is facilitated by the availability of the hypusine-containing translational factor eIF5A, necessary for the maturation of antigen-presenting cells. Treatment with agents capable of interfering with the mRNA translating iNOS or with agents that can interfere with the hypusination of eIF5A, prevents the death of islets, lowers blood glucose levels, avoids insulin resistance, and generally avoids the inflammatory response in islets associated with type 1 and type 2 diabetes.

Подробнее
02-08-2012 дата публикации

Beta 2 Adrenergic Receptor Agonists Such As Terbutaline for Use in the Treatment of Nocturnal Hypoglycemia

Номер: US20120196938A1
Автор: Guy Vergnault
Принадлежит: JAGOTEC AG

The invention is concerned with methods, regimens and dosage forms employing a beta 2 adrenergic receptor agonist such as terbutaline sulphate, for treating nocturnal hypoglycaemia in human subjects whilst reducing incidence of hyperglycaemia in said subjects upon wakening.

Подробнее
09-08-2012 дата публикации

Use of Anti-DKK-1 Monoclonal Antibodies for the Treatment of Liver Cancer

Номер: US20120201810A1
Принадлежит: Individual

The invention provides a method of treating liver cancer comprising administering anti-DKK1 monoclonal antibody to a subject in need thereof. Anti-DKK1 monoclonal antibody can also be administered for preventing or ameliorating cancer metastasis and for neutralizing serum and tissue DKK1 in liver cancer patients. The use of anti-DKK1 monoclonal antibodies is based on the discovery of the upregulation of DKK1 in human liver cancer.

Подробнее
09-08-2012 дата публикации

Transdermal delivery patch

Номер: US20120201891A1
Принадлежит: Phosphagenics Ltd

A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.

Подробнее
09-08-2012 дата публикации

Methods and devices for the sustained release of multiple drugs

Номер: US20120202742A1

The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.

Подробнее